
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. reported a total revenue of $44 million, reflecting a 15% year-over-year increase in constant currency, indicating a steady growth trajectory. The ongoing rise in gene therapy programs, particularly in oncology and rare diseases, suggests a robust market demand and an expanding pipeline of therapies, which could further enhance revenue in the coming quarters. The company is also positioned favorably as the life sciences industry grows increasingly comfortable with cell and gene therapies, which bodes well for increased commercial revenue and clinical trial activity.
Bears say
CryoPort Inc. is experiencing a concerning decline in the funding landscape for start-ups within the life sciences sector, with Series A and seed financing volumes decreasing quarter-over-quarter in 2Q:25, which could impact future growth prospects. Additionally, while the company reported a year-over-year growth in Life Sciences Services revenue, the deceleration from 21% to 16% indicates a potential trend of slowing revenue growth, compounded by anticipated headwinds in margins and profitability. Lastly, the adjustment to lower earnings per share forecasts for 2026 further underscores a negative outlook, reflecting challenges such as reduced demand for MVE freezers and fewer expected approvals in cell and gene therapy.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares